Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Research & Development (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Research & Development data on record, last reported at $27.5 million in Q4 2022.

  • For Q4 2022, Research & Development fell 52.36% year-over-year to $27.5 million; the TTM value through Dec 2022 reached $81.9 million, down 51.0%, while the annual FY2025 figure was $148.0 million, 2.72% up from the prior year.
  • Research & Development reached $27.5 million in Q4 2022 per AVIR's latest filing, up from $4.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $57.8 million in Q4 2021 and bottomed at $2.8 million in Q1 2020.
  • Average Research & Development over 3 years is $23.9 million, with a median of $23.2 million recorded in 2021.
  • Peak YoY movement for Research & Development: skyrocketed 841.9% in 2021, then plummeted 88.6% in 2022.
  • A 3-year view of Research & Development shows it stood at $13.8 million in 2020, then skyrocketed by 317.53% to $57.8 million in 2021, then tumbled by 52.36% to $27.5 million in 2022.
  • Per Business Quant database, its latest 3 readings for Research & Development were $27.5 million in Q4 2022, $4.9 million in Q3 2022, and $19.9 million in Q2 2022.